Copyright Reports & Markets. All rights reserved.

Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Citalopram (Celexa)
      • 1.4.3 Escitalopram (Lexapro)
      • 1.4.4 Fluoxetine (Prozac)
      • 1.4.5 Paroxetine (Paxil, Pexeva)
      • 1.4.6 Sertraline (Zoloft)
      • 1.4.7 Vilazodone (Viibryd)
    • 1.5 Market by Application
      • 1.5.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Share by Application (2019-2025)
      • 1.5.2 Depression
      • 1.5.3 Anxiety and panic disorder
      • 1.5.4 Other mental conditions
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size
    • 2.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Growth Trends by Regions
      • 2.2.1 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Regions (2019-2025)
      • 2.2.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by by Players
      • 3.1.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by by Players (2014-2019)
      • 3.1.2 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Concentration Ratio (CR5 and HHI)
    • 3.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Key Players Head office and Area Served
    • 3.3 Key Players Selective Serotonin Reuptake Inhibitors (SSRIs) Product/Solution/Service
    • 3.4 Date of Enter into Selective Serotonin Reuptake Inhibitors (SSRIs) Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Type (2014-2019)
    • 4.2 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size (2014-2019)
    • 5.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Key Players in North America
    • 5.3 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Type
    • 5.4 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Application

    6 Europe

    • 6.1 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size (2014-2019)
    • 6.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Key Players in Europe
    • 6.3 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Type
    • 6.4 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Application

    7 China

    • 7.1 China Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size (2014-2019)
    • 7.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Key Players in China
    • 7.3 China Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Type
    • 7.4 China Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Application

    8 Japan

    • 8.1 Japan Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size (2014-2019)
    • 8.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Key Players in Japan
    • 8.3 Japan Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Type
    • 8.4 Japan Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size (2014-2019)
    • 9.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Key Players in Southeast Asia
    • 9.3 Southeast Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Type
    • 9.4 Southeast Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Application

    10 India

    • 10.1 India Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size (2014-2019)
    • 10.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Key Players in India
    • 10.3 India Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Type
    • 10.4 India Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size (2014-2019)
    • 11.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Key Players in Central & South America
    • 11.3 Central & South America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Type
    • 11.4 Central & South America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Application

    12 International Players Profiles

    • 12.1 Allergan Plc
      • 12.1.1 Allergan Plc Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Selective Serotonin Reuptake Inhibitors (SSRIs) Introduction
      • 12.1.4 Allergan Plc Revenue in Selective Serotonin Reuptake Inhibitors (SSRIs) Business (2014-2019))
      • 12.1.5 Allergan Plc Recent Development
    • 12.2 Eli Lilly and Co.
      • 12.2.1 Eli Lilly and Co. Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Selective Serotonin Reuptake Inhibitors (SSRIs) Introduction
      • 12.2.4 Eli Lilly and Co. Revenue in Selective Serotonin Reuptake Inhibitors (SSRIs) Business (2014-2019)
      • 12.2.5 Eli Lilly and Co. Recent Development
    • 12.3 GlaxoSmithKline Plc
      • 12.3.1 GlaxoSmithKline Plc Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Selective Serotonin Reuptake Inhibitors (SSRIs) Introduction
      • 12.3.4 GlaxoSmithKline Plc Revenue in Selective Serotonin Reuptake Inhibitors (SSRIs) Business (2014-2019)
      • 12.3.5 GlaxoSmithKline Plc Recent Development
    • 12.4 H. Lundbeck AS
      • 12.4.1 H. Lundbeck AS Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Selective Serotonin Reuptake Inhibitors (SSRIs) Introduction
      • 12.4.4 H. Lundbeck AS Revenue in Selective Serotonin Reuptake Inhibitors (SSRIs) Business (2014-2019)
      • 12.4.5 H. Lundbeck AS Recent Development
    • 12.5 Pfizer Inc.
      • 12.5.1 Pfizer Inc. Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Selective Serotonin Reuptake Inhibitors (SSRIs) Introduction
      • 12.5.4 Pfizer Inc. Revenue in Selective Serotonin Reuptake Inhibitors (SSRIs) Business (2014-2019)
      • 12.5.5 Pfizer Inc. Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants. They can ease symptoms of moderate to severe depression, are relatively safe and typically cause fewer side effects than other types of antidepressants do.
      With an increase in mental illnesses, there is a rising need for effective neurological drugs. Among the various neurological drugs available in the market, SSRIs drugs have high therapeutic efficacy. As a result, the number of vendors manufacturing these drugs is increasing. Moreover, health insurance companies, with support from governments, have started covering treatment expenses related to mental disorder. The rising prevalence of mental illnesses will significantly contribute to the selective serotonin reuptake inhibitors market growth.
      In 2018, the global Selective Serotonin Reuptake Inhibitors (SSRIs) market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Selective Serotonin Reuptake Inhibitors (SSRIs) status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Selective Serotonin Reuptake Inhibitors (SSRIs) development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      Allergan Plc
      Eli Lilly and Co.
      GlaxoSmithKline Plc
      H. Lundbeck AS
      Pfizer Inc.
      ...

      Market segment by Type, the product can be split into
      Citalopram (Celexa)
      Escitalopram (Lexapro)
      Fluoxetine (Prozac)
      Paroxetine (Paxil, Pexeva)
      Sertraline (Zoloft)
      Vilazodone (Viibryd)

      Market segment by Application, split into
      Depression
      Anxiety and panic disorder
      Other mental conditions

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Selective Serotonin Reuptake Inhibitors (SSRIs) status, future forecast, growth opportunity, key market and key players.
      To present the Selective Serotonin Reuptake Inhibitors (SSRIs) development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Selective Serotonin Reuptake Inhibitors (SSRIs) are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
      Buy now